Price Disclosure Reductions for 2019 April Cycle

This summary only includes medicines taking a price disclosure reduction on 1 April 2019. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations).

The outcomes below show percentage (%) price differences and ex-manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should note that:

  • if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 April 2019 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
  • if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs in late January 2019.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their October 2018 PBS approved ex-manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of existing pharmaceutical items with a determination in Schedule 1 that listed after 30 September 2018 will also take the reduction on 1 April 2019 under section 99ADHA of the Act.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEDT on 21 December 2018. 

Indicative prices for 1 April 2019 (including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published by late January 2019. Subscribe to PBS News to receive notice when they become available.

Final prices for 1 April 2019 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from early March 2019.

2019 April Cycle Outcomes Summary
Legal Instrument Drug
(drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria) 		Legal
Instrument
MoA 		Legal Instrument Form Average
AEMP
($) 		WAPD
(%)
across a
drug/MoA 		WADP -
potential
April '19
PBS Price (AEMP)
($) per
pharmaceutical
item 		October '18
AEMP
($) 		Percentage difference between October '18 and April '19  PBS prices (AEMP) (%) per
pharmaceutical item 		Calculations based on:

OWAPD = all brand data

GWAPD = originator brand data removed for at least one pharmaceutical item

No originator brand determined

Does not meet 30 month clock 		Applicable Unadjusted Price Reduction
10% or 30%
[Average AEMP minus WAPD = WADP]   [Difference between October '18
AEMP & WADP = % Difference]
Aripiprazole Oral Tablet 10 mg 88.33 15.69% 74.47 88.33 15.69% OWAPD 10
Aripiprazole Oral Tablet 15 mg 125.35 15.69% 105.68 125.35 15.69% OWAPD 10
Aripiprazole Oral Tablet 20 mg 152.58 15.69% 128.64 152.58 15.69% OWAPD 10
Aripiprazole Oral Tablet 30 mg 185.93 15.69% 156.76 185.93 15.69% OWAPD 10
Atomoxetine Oral Capsule 10 mg (as hydrochloride) 56.67 26.51% 41.65 56.67 26.50% OWAPD 10
Atomoxetine Oral Capsule 100 mg (as hydrochloride) 73.67 26.51% 54.14 73.67 26.51% OWAPD 10
Atomoxetine Oral Capsule 18 mg (as hydrochloride) 56.67 26.51% 41.65 56.67 26.50% OWAPD 10
Atomoxetine Oral Capsule 25 mg (as hydrochloride) 56.67 26.51% 41.65 56.67 26.50% OWAPD 10
Atomoxetine Oral Capsule 40 mg (as hydrochloride) 56.67 26.51% 41.65 56.67 26.50% OWAPD 10
Atomoxetine Oral Capsule 60 mg (as hydrochloride) 56.67 26.51% 41.65 56.67 26.50% OWAPD 10
Atomoxetine Oral Capsule 80 mg (as hydrochloride) 73.67 26.51% 54.14 73.67 26.51% OWAPD 10
Azacitidine Injection Powder for injection 100 mg 317.31 31.41% 217.64 270.02 19.40% OWAPD 10
Baclofen Injection Intrathecal injection 10 mg in 5 mL 124.63 10.71% 111.28 124.63 10.71% OWAPD 10
Baclofen Injection Intrathecal injection 40 mg in 20 mL 498.40 10.71% 445.02 498.40 10.71% OWAPD 10
Celecoxib Oral Capsule 100 mg 5.23 12.03% 4.60 5.23 12.05% GWAPD 10
Celecoxib Oral Capsule 200 mg 5.23 12.03% 4.60 5.23 12.05% GWAPD 10
Desvenlafaxine Oral Tablet (extended release) 100 mg (as succinate) 13.21 12.04% 11.62 13.21 12.04% OWAPD 10
Desvenlafaxine Oral Tablet (extended release) 50 mg (as succinate) 10.76 12.04% 9.46 10.76 12.08% OWAPD 10
Desvenlafaxine Oral Tablet (modified release) 100 mg 13.21 12.04% 11.62 13.21 12.04% OWAPD 10
Desvenlafaxine Oral Tablet (modified release) 100 mg (as benzoate) 13.21 12.04% 11.62 13.21 12.04% OWAPD 10
Desvenlafaxine Oral Tablet (modified release) 50 mg 10.76 12.04% 9.46 10.76 12.08% OWAPD 10
Desvenlafaxine Oral Tablet (modified release) 50 mg (as benzoate) 10.76 12.04% 9.46 10.76 12.08% OWAPD 10
Entecavir Oral Tablet 0.5 mg (as monohydrate) 234.64 28.04% 168.85 210.81 19.90% OWAPD 10
Entecavir Oral Tablet 1 mg (as monohydrate) 381.59 28.04% 274.59 342.84 19.91% OWAPD 10
Epirubicin Injection/Intravesical Solution for injection containing epirubicin hydrochloride 100 mg in 50 mL 58.22 44.88% 32.09 58.22 44.88% OWAPD 30
Epirubicin Injection/Intravesical Solution for injection containing epirubicin hydrochloride 200 mg in 100 mL 116.44 44.88% 64.18 116.44 44.88% OWAPD 30
Epirubicin Injection/Intravesical Solution for injection containing epirubicin hydrochloride 50 mg in 25 mL 29.11 44.88% 16.05 29.11 44.86% OWAPD 30
Epoprostenol* Injection Powder for I.V. infusion 1.5 mg (as sodium) 66.55 10.85% 59.33 66.55 10.85% OWAPD 10
Epoprostenol* Injection Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL 66.55 10.85% 59.33 66.55 10.85% OWAPD 10
Epoprostenol* Injection Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL 33.28 10.85% 29.67 33.28 10.85% OWAPD 10
Filgrastim Injection Injection 120 micrograms in 0.2 mL single use pre-filled syringe (Nivestim) 182.87 32.28% 123.84 182.87 32.28% OWAPD 30
Filgrastim Injection Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Neupogen) 457.18 32.28% 309.60 457.18 32.28% OWAPD 30
Filgrastim Injection Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Nivestim) 457.18 32.28% 309.60 457.18 32.28% OWAPD 30
Filgrastim Injection Injection 300 micrograms in 0.5 mL single use pre-filled syringe (TevaGrastim) 457.18 32.28% 309.60 457.18 32.28% OWAPD 30
Filgrastim Injection Injection 300 micrograms in 0.5 mL single use pre-filled syringe (Zarzio) 228.59 32.28% 154.80 228.59 32.28% OWAPD 30
Filgrastim Injection Injection 300 micrograms in 1 mL 457.18 32.28% 309.60 457.18 32.28% OWAPD 30
Filgrastim Injection Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Neupogen) 732.89 32.28% 496.31 732.89 32.28% OWAPD 30
Filgrastim Injection Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Nivestim) 732.89 32.28% 496.31 732.89 32.28% OWAPD 30
Filgrastim Injection Injection 480 micrograms in 0.5 mL single use pre-filled syringe (Zarzio) 366.44 32.28% 248.15 366.44 32.28% OWAPD 30
Filgrastim Injection Injection 480 micrograms in 0.8 mL single use pre-filled syringe (TevaGrastim) 732.89 32.28% 496.31 732.89 32.28% OWAPD 30
Filgrastim Injection Injection 480 micrograms in 1.6 mL 732.89 32.28% 496.31 732.89 32.28% OWAPD 30
Ganciclovir Injection Powder for I.V. infusion 500 mg (as sodium) 223.44 10.19% 200.67 223.44 10.19% OWAPD 10
Idarubicin Injection Solution for I.V. injection containing idarubicin hydrochloride 10 mg in 10 mL 70.47 37.50% 44.04 70.47 37.51% GWAPD 30
Idarubicin Injection Solution for I.V. injection containing idarubicin hydrochloride 5 mg in 5 mL 36.45 37.50% 22.78 36.45 37.50% GWAPD 30
Irinotecan Injection I.V. injection containing irinotecan hydrochloride trihydrate 100 mg in 5 mL 13.42 39.56% 8.11 13.42 39.57% OWAPD 30
Irinotecan Injection I.V. injection containing irinotecan hydrochloride trihydrate 40 mg in 2 mL 5.37 39.56% 3.25 5.37 39.48% OWAPD 30
Irinotecan Injection I.V. injection containing irinotecan hydrochloride trihydrate 500 mg in 25 mL 67.12 39.56% 40.57 67.12 39.56% OWAPD 30
Naloxone Injection Injection containing naloxone hydrochloride 2 mg in 2 mL pre-filled syringe 43.12 20.32% 34.36 43.12 20.32% OWAPD 10
Naloxone Injection Injection containing naloxone hydrochloride 400 micrograms in 1 mL ampoule 48.89 20.32% 38.96 48.89 20.31% OWAPD 10
Olmesartan Oral Tablet containing olmesartan medoxomil 20 mg 5.63 22.85% 4.34 5.63 22.91% OWAPD 10
Olmesartan Oral Tablet containing olmesartan medoxomil 40 mg 11.94 22.85% 9.21 11.94 22.86% OWAPD 10
Olmesartan with hydrochlorothiazide Oral Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg 7.07 18.67% 5.75 7.07 18.67% OWAPD 10
Olmesartan with hydrochlorothiazide Oral Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg 13.38 18.67% 10.88 13.38 18.68% OWAPD 10
Olmesartan with hydrochlorothiazide Oral Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg 14.81 18.67% 12.04 14.81 18.70% OWAPD 10
Pemetrexed Injection Powder for I.V. infusion 1 g (as disodium) 131.35 41.66% 76.63 92.43 17.09% OWAPD 10
Pemetrexed Injection Powder for I.V. infusion 100 mg (as disodium) 13.14 41.66% 7.67 9.24 16.99% OWAPD 10
Pemetrexed Injection Powder for I.V. infusion 500 mg (as disodium) 65.67 41.66% 38.31 46.21 17.10% OWAPD 10
Tenofovir with emtricitabine Oral Tablet containing tenofovir disoproxil fumarate 300 mg with emtricitabine 200 mg 220.34 34.82% 143.62 220.34 34.82% OWAPD 10
Tenofovir with emtricitabine Oral Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg 220.34 34.82% 143.62 220.34 34.82% OWAPD 10
Tenofovir with emtricitabine Oral Tablet containing tenofovir disoproxil phosphate 291 mg with emtricitabine 200 mg 220.34 34.82% 143.62 220.34 34.82% OWAPD 10
Valganciclovir Oral Tablet 450 mg (as hydrochloride) 1792.15 41.92% 1040.88 1506.30 30.90% OWAPD 10
Voriconazole Oral Tablet 200 mg 1276.15 24.97% 957.50 1276.15 24.97% OWAPD 10
Voriconazole Oral Tablet 50 mg 319.04 24.97% 239.38 319.04 24.97% OWAPD 10

 

Confirmed prices of brands scheduled for a price disclosure reduction

The Confirmed Prices Report outlines the approved ex-manufacturer prices for brands scheduled to take a price disclosure reduction. The reports for the 2019 April cycle can be downloaded below.

Last updated
27 March 2019